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Context:Estrogens amplify spontaneous and stimulated growth hormone (GH) secretion, whereas they
diminish GH-dependent insulin-like growth factor (IGF)-I in a dose-dependent manner. Selective es-
trogen receptor modulators (SERMs), including tamoxifen and toremifene, are widely adjunctively used
in breast and prostate cancer. Although some endocrine effects of tamoxifen are known, few data are
available for toremifene.
Objective: To explore sex-dependent effects of toremifene on spontaneous 10-hour overnight GH se-
cretion, followed by GH-releasing hormone–ghrelin stimulation. Additionally, effects on IGF-I, its
binding proteins, and sex hormone–binding globulin (SHBG) were quantified.
Participants and Design: Twenty men and 20 women, within an allowable age range of 50 to 80 years,
volunteered for this double-blind, placebo-controlled prospective crossover study. Ten-minute blood sampling
wasdone for10hoursovernightand then for2hoursafter combinedGH-releasinghormone–ghrelin injection.
MainOutcomeMeasures:Pulsatile GHand stimulatedGHsecretion, and fasting levels of IGF-I, IGF-
binding protein (IGFBP)1, IGFBP3, and SHBG.
Results: Toremifene did not enhance pulsatile or stimulated GH secretion, but decreased IGF-I by 20%
inmen and women. IGFBP3was unchanged, whereas while IGFBP1 and SHBG increased in both sexes
to a similar extent.
Conclusions: The expected rise in spontaneous and stimulated GH secretion under the diminished
negative feedback restraint of powered IGF-I favors a central inhibitory antiestrogenic effect of tor-
emifene. Estrogenic effects of toremifene on the liver were present, as evidenced by increased IGFBP1
and SHBG levels. Men and women responded to this SERM comparably.
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Pulsatile growth hormone (GH) secretion in humans is regulated by the time-dependent
interplay between the stimulating neuropeptide GH-releasing hormone (GHRH) and the
inhibitory neuropeptide somatostatin. Additionally, many other factors impact this sys-
tem, including negative feedback by liver-derived circulating insulin-like growth factor
(IGF)-I and GH, stimulating action by hypothalamic and gastric secretion of acylated
ghrelin, the active form of ghrelin, and inhibition by free fatty acids [1]. Clinical studies
indicate that estradiol regulates hypothalamic–pituitary responses to each of these pep-
tides [2–4]. The highest GH levels in humans are present at birth and at puberty,
whereafter serumGH levels decrease steadily, together with testosterone, estradiol, IGF-I,
and IGF-binding protein (IGFBP)3 concentrations. Relative sex-steroid deprivation ac-
centuates GH and IGF-I depletion, because testosterone stimulates GH and IGF-I in older
men, hypogonadal males of all ages, and patients undergoing (genotypic female-to-male)
gender reassignment [1, 5]. The estrogen receptor antagonist, tamoxifen, blocks this effect
of testosterone, suggesting involvement of estradiol in the stimulation of GH at least in
young men [6].
Selective estrogen receptor modulators (SERMs) are crucial for the treatment of
metastasized breast carcinoma in postmenopausal women [7, 8]. In breast tissue, this
class of nonsteroidal drugs is antiestrogenic, but in other tissues it may have estrogenic
effects (e.g., liver, uterus, and bone). The first SERM that became available for clinical
use was tamoxifen; since then, other SERMs, including toremifene, have been developed
with the expectation of a more favorable action profile. The chemical structure of tor-
emifene is identical to that of tamoxifen except for a chlorine atom at position 4. SERMs
are also used adjunctively for treatment of symptomatic gynecomastia in testosterone-
depleted men with prostatic cancer, as well as for prevention of osteoporosis and bone
metastases [9, 10].
The effects of SERMs on the endocrine system have not been studied in detail. Scattered
reports mention decreased serum gonadotropin levels, increased sex hormone–binding
globulin (SHBG), and increased IGFBP-1 levels [11, 12], but the GH/IGF-I axis has not been
evaluated comprehensively in detail in spite of the changed estrogenic milieu [12, 13].
Antiestrogenic effects of toremifene could attenuate GH secretion and IGF-I production, thus
favoring the development of the metabolic syndrome in patients treated long-term with
SERMS.
The primary endpoint of this study is spontaneous GH secretion, estimated by overnight
blood sampling at 10-minute intervals and GH release induced by GH secretagogues, sep-
arately in men and women to test sex dependence. Secondary endpoints are circulating
concentrations of liver-dependent proteins (e.g. IGF-I), the binding proteins IGFBP-1 and
IGFBP-3 and SHBG, and the effects on basal levels of gonadotropins, prolactin, estrogens,
and insulin resistance.
1. Material and Methods
A. Subjects
Twenty healthy, ambulatory community-dwelling older men (mean age, 65.5 years; range, 60
to 75 years) and 20 healthy postmenopausalwomen [mean age, 64 years; range, 53 to 73 years,
and clinically defined by estradiol, 50 pg/mL, follicle-stimulating hormone (FSH). 30 IU/L]
participated in the overnight Clinical Research Unit–based study. The body mass index in
men was 26.5 kg/m2 (range, 23 to 33 kg/m2) and in women it was 25.6 kg/m2 (range, 18 to
36.7 kg/m2). Volunteers were recruited by newspaper advertisements, local posters, the
Clinical Trials Center Web page, and community (general and minority) bulletin boards. The
key randomization in this double-blind, placebo-controlled prospective crossover study was
oral placebo vs oral toremifene [60 mg taken once daily for 10 (62) days, followed, after a
3-week washout interval, by the other agent]. Both men and women were studied in a
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crossover design within sex. Each subject underwent two 12-hour overnight 10-minute blood
sampling procedures from 2200 hours until 1000 hours in the Clinical ResearchUnit. A single
combined injection of GHRH/ghrelin (both doses 0.3 mg/kg) was given by intravenous bolus at
0800 hours to test pituitary effects of the estrogen protocols. Overnight GH sampling is
performed because .80% of total GH is secreted overnight.
To reduce nutritional confounds, volunteers were given a prescribed meal to ingest on the
evening before the sampling session.Men received a standardized 10 kcal/kgmeal andwomen
an 8 kcal/kg meal (vegetarian or nonvegetarian) with a macronutrient composition of 20%
protein, 50% carbohydrate, and 30% fat. Participants then remained fasting overnight (except
for allowable intake of noncaloric and noncaffeinated liquids) until 1000 hours the next day.
Subjects arrived in the Clinical Research Unit at or before 1800 hours to permit placement of
bilateral forearm intravenous catheters. A blood sample was obtained at 0800 hours for
baseline sex hormone and peptide measurements. Ambulation was allowed to the lavatory.
The volunteer was allowed to sleep during the sampling window. Breakfast was offered after
1000 hours before discharge from the unit.
The protocol was approved by Mayo Institutional Review Board. Witnessed voluntary
written consent was obtained before study enrollment. A complete medical history, physical
examination, and screening tests of hematological, renal, hepatic, metabolic, and endocrine
function were normal. Subjects underwent a single-slice computed tomography of the ab-
domen, level L3 to L4, as an exploratory measure to evaluate the impact of relative visceral
obesity on GH responses. Existing data indicate that visceral fat mass is a key negative
determinant of daily GH secretion, but the relative impact on specific secretagogue responses
is unexplored. Visceral fat mass inmen was 1786 17 cm2 and was 956 13 cm2 in women (P =
0.001). In one female volunteer, 10-minute blood sampling during the placebo phase was
incomplete due to technical problems.
B. Materials
Human GHRH was obtained from Bachem Americas (Torrance, CA). Ghrelin from C.S. Bio
(Menlo Park, CA), and toremifene was from GTx (Memphis, TN).
C. Exclusion Criteria
Exclusion criteria were acute or chronic systemic diseases, HIV positivity by medical history,
anemia, endocrine disorders (except hypothyroid subjects who were biochemically euthyroid
on replacement), psychiatric illness, alcohol or drug abuse, history or suspicion of prostatic
disease [elevated prostate-specific antigen (.4.0 ng/mL)], obstructive uropathy, deep venous
or arterial thromboses, cancer of any type (except localized basal or squamous cell cancer of
the skin treated surgically without recurrence), allergy to medications used in the study,
significant recent weight change (loss/gain of 6 or more pounds during 6 weeks), trans-
meridian travel (exceeding three time zones within the preceding 3 weeks), systemic drugs,
abnormal renal, hepatic, or hematologic function, concomitant sex hormone replacement,
pregnancy or lactation, and unwillingness to provide written informed consent.
D. Assays
The 10-minute serum samples were assayed in a single batch in each subject by chem-
iluminescence GH assay, performed using a Beckman Coulter robotics Access ultrasensitive
human GH assay (Beckman Instruments, Chaska, MN). Within-assay precision was 3.8% to
6.5% (range of 100 runs), sensitivity 0.010mg/L, and specificity 97% 22-kDaGH. The following
hormones and peptides were measured in the 0800 hours fasting blood specimen. Estrone,
estradiol, and high-precision testosterone were measured with liquid chromatography–
tandemmass spectrometry (Agilent Technologies, SantaClara, CA). Interassay coefficients of
variation (CVs) were: estrone, 12% at 0.25 pg/mL and 7.4% at 30 pg/mL; estradiol, 10.8% at
0.29 pg/mL and 5.1%at 32 pg/mL; testosterone, 8.9%at 0.69 ng/dL, 4.0%at 45 ng/dL, and 3.5%
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at 841ng/dL. IGF-I, IGFBP3, andSHBGwere quantified by solid-phase chemiluminescent assay
on the Siemens Immulite 2000 automated immunoassay system (Siemens Healthcare Di-
agnostics, Deerfield, IL). Interassay CVs for IGF-I are 4.9% at 37 ng/mL and 5% at 225 mg/L; for
IGFBP3, 4% and 3.9% at 1.0 and 4.3 mg/L, respectively; and for SHBG, 4.0% at 5.4 nmol/L and
5.9% at 74 nmol/L. IGFBP1 was determined by a two-site immunoradiometric assay (Diagnostic
SystemsLaboratories,Webster, TX). InterassayCVs are 10.2%at 0.49mg/L and6.7%at 4.5mg/L.
Insulin wasmeasured by a two-site immunoenzymatic sandwich assay on the Roche e411
(Roche Diagnostics, Indianapolis, IN). Interassay CVs are 3.3%, 2.8%, and 2.5% at 18, 61,
and 172 mU/L. Prolactin, FSH, and luteinizing hormone (LH) were measured by two-site
chemiluminescent sandwich immunoassays on a DXL 800 automated immunoassay system
(Beckman Instruments, Chaska,MN). For prolactin, the interassay CVs are 3.7%, 2,1%, and
4.8% at 6.1, 16.4, and 34.5 mg/L, respectively; for FSH, the interassay CVs are 3.6%, 3.2%,
and 4.7% at 6.5, 16.7, and 58.0 IU/L, respectively; and for LH, interassayCVs are 9.3%, 6.0%,
and 6.0% at 1.4, 15.6, and 48.8 IU/L, respectively. Free testosterone levels were calculated
on the basis of SHBG and albumin concentrations [14].
E. Secondary Analyses
E-1. Deconvolution of 10-minute GH concentration profiles
Variable-waveform deconvolution analysis was used to reconstruct secretion into underlying
trains of secretory bursts, superimposed upon basal (time-invariant) secretion, allowing
biexponential elimination (fixed fast half-life for rapid diffusion and advection, and estimated
slow half-life for delayedmetabolic elimination). The analysis implements aMATLAB-based,
adaptive-mesh, multiparameter-search algorithm cross-validated earlier [15].
E-2. Approximate entropy
Secretory regularity ofGHsecretionwasappraisedvia theapproximate entropy (ApEn) statistic.
This metric provides a sensitive (.90%) and specific (.90%) model-free and scale-invariant
measure of relative randomness, due to loss of feedback control within a network [16, 17].
F. Statistical Analysis
The primary endpoints were pulsatile GH secretion determined from the 10-hour serum
concentration profiles before and the 2-hour profiles after combined GHRH/ghrelin injection.
Secondary outcomes were effects on serum levels of IGF-I and its binding proteins.
Data were analyzed using a generalized linear model (GLM) comprising two-way analysis
of covariance with repeated measures. The categorical variables were sex (two factors),
toremifene or placebo administration (two factors), and age, visceral fat, mean 10-hour GH
concentration, and, where indicated, serum insulin and estrone and estradiol concentrations
as covariates. Linear regression analysis was used to identify significant predictors of the
liver proteins during placebo and toremifene treatment. Calculations were performed with
Systat 13 (Systat Software, San Jose, CA) and MATLAB 8.6 (MathWorks, Natick, MA). A
P value , 0.01 was construed as significant for the overall study.
2. Results
The 10-hour GH concentration profiles in men and women during placebo and toremifene
administration are shown in Fig. 1. The upper two panels illustrate GH secretion before the
injection of GHRH/ghrelin, and the lower two panels reflect GH release after intravenous
administration of the GH secretagogues. The results of the deconvolution analyses, sepa-
rately formen andwomen, are shown in Table 1. GH levels tended to be higher inwomen than
in men, especially after GHRH/ghrelin administration.
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Pulsatile GH secretion is the major mediator of biological effects, and therefore any effect
on its secretion by the SERM toremifene is clinically relevant. In the GLM there were no drug
or drug–sex interaction effects [P = 0.29 and 0.46, analysis of variance (ANOVA) P = 0.19]. In
general, age and visceral fat are negative determinants of (pulsatile) GH secretion. Therefore,
in the full GLM, both variables were used as covariates, wherein age ranged from 53 to
75 years, whereas visceral fat mass ranged from 13 to 330 cm2. Therein, toremifene did not
alter GH secretion (P = 0.87) or interact with sex, age, or visceral fat (P = 0.30, 0.73, and 0.41,
respectively). Comparable results were obtained for basal GH secretion, total (pulsatile plus
basal) GH secretion, mean GH pulse mass, and mean 10-hour GH concentration (detailed
statistical results are not shown).
GHRH/ghrelin evoked an acute rise in GH concentrations, and this effect was larger in
women thanmen (Fig. 1; Table 1). Toremifene did not alter this response, whether sexes were
tested combined or separately. In the full GLM procedure toremifene administration also did
not alter GH secretion (P = 0.70) or interact with other factors (sex P = 0.65, visceral fat P =
0.86, age P = 0.77). Also, other procedures to estimate the GH response after the adminis-
tration of the GH secretagogues, that is, the difference between the 12-hour and 10-hour total
and pulsatile secretion, resulted in the same outcome (data not shown).
The effect of toremifene on IGFBPs is listed in Table 2. IGF-I concentrations decreased by
~20% inmen andwomen during the administration of the oral SERM toremifene. In the GLM
procedure, treatment with toremifene was a significant factor (P = 0.01) without interactions
by age, sex, and visceral fat mass. IGFBP1 concentrations increased by 1.5-fold inmen and by
2.9-fold in women (P, 0.0001), and with a significant interaction with visceral fat (P = 0.001).
In contrast, the small increase (4%) in IGFBP3 levels was borderline significant in men and
women (P = 0.032). Sex hormone–binding globulin increased by 23% and 20% in men and
women, respectively (P, 0.01). Estrone, estradiol, prolactin, insulin levels, and homeostatic
model assessment of insulin resistance remained statistically unchanged under toremifene
administration. There was a decrease in gonadotropin levels (14% to 17%) in women only
(Table 2).
Regression analyses were done to test whether other factors influenced IGF-I and IGFBP1
during placebo and verum treatment (Fig. 2). Significant predictors of IGF-I during placebo
were age (b =22.756 0.87, P = 0.004) and mean 10-hour GH concentration (b = 50.66 12.4,
P , 0.0001) and borderline for visceral fat (b = 0.1696 0.063, P = 0.01) (overall ANOVA P ,
0.0001). Regressions were not significant for IGF-I or estrone and estradiol. During tor-
emifene treatment, only the mean GH concentration was a significant predictor of IGF-I (b =
54.46 13.7, P = 0.001) (ANOVA P = 0.001). Age was a weak predictor (P = 0.04), but visceral
fat mass was not (P = 0.06). A strong predictor of IGFBP1 during the placebo phase was the
fasting insulin level (b =20.3666 0.100, P = 0.001), whereas age was a weak predictor (b =
20.1386 0.64,P=0.037) (ANOVAP= 0.002). Visceral fatmasswas also a predictor (P=0.005),
and its interaction with insulin was highly significant (P = 0.007), owing to a positive cor-
relation between these variables (R = 0.65,P, 0.0001). During toremifene treatment, insulin
was still a strongly negative predictor (b = 21.151 6 0.289, P , 0.0001), along with age (b =
0.206 6 0.075, P = 0.01) and visceral fat (b = 20.051 6 0.013, P , 0.001). Indeed, the in-
teraction factor insulin times visceral fat was highly significant (P = 0.005), owing to positive
correlation between these two variables (R = 0.51, ANOVA P = 0.001). Finally, the factors
impacting the change in IGF-I and IGFBP1 levels were also analyzed in regressionmodels. In
the regression analyses, the change in IGF-I levels during placebo and toremifene treatment,
expressed as an algebraic increase (D) or as their ratio, for visceral fat mass was a borderline
and nonsignificant predictor (P = 0.035 and P = 0.15, respectively). Age, mean GH concen-
tration, estrone, and estradiol levels were nonsignificant. For DIGFBP1 only insulin was a
predictor (P , 0.0001) but not for the ratio.
Because of the decrease in IGF-I levels during toremifene treatment, feedback is di-
minished, and therefore an increase in GH ApEn was expected. However, ApEn was un-
changed between placebo (0.791 6 0.041) and toremifene treatment (0.758 6 0.043). In the
GLM procedure, treatment, sex, and age were all nonsignificant predictors for ApEn.
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Figure 1. Measured GH time series in men and women (N = 40 total). Blood samples were
drawn at 10-minute intervals, starting at 2200 hours until 0800 hours (upper two panels). At
0800 hours, the subjects received a bolus injection of 0.3 mg/kg of both GHRH and ghrelin
and sampling was continued for another 2 hours. GH secretion under placebo and toremifene
did differ significantly. Note differences in y-axis scales.
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3. Discussion
The salient outcome of this study is that toremifene, a widely used SERM in the treatment of
breast cancer in postmenopausal women and for the treatment of symptomatic gynecomastia
in androgen-deprived men with prostate carcinoma, does not augment or attenuate spon-
taneous and stimulated GH secretion. Estrogens play a major role in amplifying GH secre-
tion in many species, including humans, via activating the a-type estrogen receptor of the
somatotropes and GHRH-secreting neurons. The physiological role of 17b-estradiol is
underscored by increasing GH secretion during the menstrual cycle, coupled to prevailing
serum estradiol concentrations, the amplified GH secretion in girls with Turner syndrome
treated with estrogen, and the GH-promoting effect in subjects undergoing male-to-female
transition [18–20]. Furthermore, blocking the estrogen receptor with fulvestrant decreases
GH secretion by one-third in estrogen-replete postmenopausal women, underscoring the vital
role of estrogen receptors in the hypothalamus and pituitary gland [21]. However, the bi-
ological importance of estradiol is not restricted to women, but also applies to men, wherein
Table 1. GH Secretion Estimated by Deconvolution Analysis of 10-Hour GH Concentration Profiles
Placebo Toremifene
Men Women Men Women
Basal secretion, mg/L/10 h 3.8 6 0.6 5.6 6 1.5 3.2 6 0.5 3.0 6 1.1
Pulsatile secretion, mg/L/10 h 15.9 6 2.6 19.2 6 3.4 13.0 6 1.7 18.5 6 2.6
Total secretion, mg/L/10 h 19.7 6 3.1 24.9 6 4.6 16.2 6 2.0 23.5 6 3.5
Mean pulse mass, mg/L 2.9 6 0.5 3.7 6 0.7 2.8 6 0.5 3.4 6 0.5
Half-life, min 14.9 6 0.9 13.7 6 1.1 14.1 6 1.0 15.4 6 1.2
Mode, min 15.4 6 0.8 15.9 6 1.0 16.2 6 1.2 15.9 6 0.8
GHRH/ghrelin-stimulated pulse mass, mg/L 8.4 6 1.1 20.8 6 4.2a 11.4 6 2.2 20.9 6 3.6b
Mean 10-hour concentration, mg/L 0.49 6 0.08 0.60 6 0.01 0.43 6 0.07 0.63 6 0.09c
Data aremean6 standard error of themean. Statistical differences betweenmen andwomenwerewith the unpaired
two-tailed Student. t test.
aP = 0.02.
bP = 0.01.
cP = 0.03.
Table 2. Fasting Serum Peptide and Hormone Concentrations
Hormone/Peptide
Women Men
Placebo Toremifene P Value Placebo Toremifene P Value
Estrone, pg/mL 18.3 6 2.1 19.0 6 2.1 0.34 22.1 6 1.4 23.9 6 1.7 0.11
Estradiol, pg/mL 3.28 6 0.33 3.37 6 0.30 0.46 17.7 6 1.1 19.3 6 1.3 0.22
IGF-I, mg/L 105 6 7.4 84 6 7.5 ,0.0001 108 6 6.7 85 6 5.1 ,0.0001
BP3, mg/L 3.82 6 0.19 3.91 6 0.19 0.17 3.17 6 0.13 3.31 6 0.13 0.07
BP1, mg/L 3.69 6 0.71 6.02 6 0.89 ,0.0001 2.80 6 0.30 4.29 6 0.48 ,0.0001
Insulin, mU/L 6.38 6 0.96 6.67 6 0.87 0.61 7.30 6 0.87 6.89 6 0.80 0.51
Prolactin, mg/L 8.21 6 0.86 7.59 6 0.75 0.46 7.98 6 0.73 6.73 6 0.47 0.03
SHBG, nmol/L 59 6 6.3 71 6 6.8 ,0.0001 43 6 2.6 52 6 3.9 ,0.0001
LH, IU/L 22.5 6 2.3 19.4 6 1.4 0.026 5.6 6 1.3 5.9 6 0.9 0.82
FSH, IU/L 62.0 6 5.2 52.0 6 4.0 0.001 8.1 6 1.8 9.0 6 1.5 0.22
HOMA-IR 1.50 6 0.25 1.52 6 0.22 0.88 1.61 6 0.20 1.58 6 0.18 0.80
Total testosterone, ng/dL 18.7 6 2.5 18.0 6 2.4 0.90 402 6 29 455 6 28 0.012
Free testosterone, ng/dL NC NC 7.42 6 0.53 7.61 6 0.48 0.70
Bioavailable testosterone, ng/dL NC NC 153 6 11 156 6 10 0.77
Data are mean 6SEM. A Student two-tailed t test for paired observations was used. P values are for ANOVA.
Abbreviations: HOMA-IR, homeostatic model assessment of insulin resistance; NC, not calculated.
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testosterone is locally aromatized to 17b-estradiol in brain [6, 22]. Aromatase inhibition with
anastrozole leads to diminished GH secretion in men, whereas administration of non-
aromatizable androgens in hypogonadalmen does not increase GH secretion [23]. Finally, the
aromatase-knockout mouse has downregulated GH synthesis in somatotropes, which can be
reversed by estradiol [24].
SERMs have partial agonistic and partial antagonistic effects, depending on the tissue
involved, and probably also to the presence of a- and b-estrogen receptors. Nongenomic
mechanisms may also play a role via the G protein–coupled estrogen receptor [25]. The
endocrine effects of toremifene have not been studied well. In particular, no GH data could be
found after extensive literature search, only a comment that fastingGH levels increase during
toremifene treatment [12]. Nevertheless, limited GH data are available for tamoxifen, a
SERMwith similarity to toremifene, except for a chlorine atom at position 4 of themolecule. It
seemed reasonable to assume that the pharmacokinetic profile of these two drugs would not
differ greatly. In a small study comprising six postmenopausal womenwith breast carcinoma,
chronic administration of tamoxifen numerically but nonsignificantly diminished the GH
Figure 2. Serum IGF-I concentrations (vertical axis) plotted vs mean serum overnight GH
concentration (mean of 60 samples) and age (horizontal and oblique axes) during placebo and
toremifene treatment (upper two panels). The lower two panels show the regression between
serum IGFBP1 concentration (vertical axis) and visceral fat and fasting insulin (horizontal and
oblique axes) during placebo and toremifene treatment. Note differences in vertical axes scales.
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response to a 50-mgGHRHbolus [26]. In other studies tamoxifen decreasedGH secretion after
arginine infusion in women, but not significantly in men [27, 28]. The sex difference in GH
response was attributed to the 1.5-fold increase in serum total testosterone concentration in
men on tamoxifen, providing more substrate for local conversion into estradiol [28]. In the
present study, we also noted increased testosterone levels in men, but here the rise was fully
attributable to the increased SHBG levels. Specifically, both bioavailable and free testos-
terone concentrations remained unchanged under toremifene in our study. Another study in
10 postmenopausal women after mastectomy for breast cancer reported diminished GHRH-
stimulated GH secretion after 6 to 12 months treatment with 20 mg of tamoxifen [29]. In line
with our study, another SERM, raloxifene, did not change the GH response to L-arginine
infusion in men and women, but exhibited well-known estrogenic liver effects on SHBG and
IGF-I [28]. Therefore, the hormonal effects of toremifene resemble those of raloxifene.
In contrast to all other earlier studies evaluating the effect of SERMs onGH,we did not rely
exclusively on GH stimulation to infer conclusions about overall GH production. Instead, the
present study estimated GH secretion overnight, when most (.85%) of the 24-hour secretion
takes place. One elegant study has shown that the administration of different types of es-
trogens (ethinyl estradiol, conjugated equine estrogen, and estradiol valerate) causes di-
minished IGF-I levels in healthy postmenopausal women and that the IGF-I decrease is
correlated with the increase in the mean 24-hour serum GH concentration [30]. The observed
20% decrease in serum IGF-I concentrations found in our study was accompanied by un-
changed IGFBP3 and increased IGFBP1 levels. These changes are expected to decrease free
and biologically available IGF-I. Diminished IGF-I feedback should have led to increased GH
secretion in our male and female volunteers. Therefore, the absence of any GH amplification
during overnight blood sampling and after injection of GHRH/ghrelin as a strong stimulus
suggests a central antagonistic estrogenic effect of toremifene. This might also explain the
unchanged approximate entropy of GH profiles, which should have increased under di-
minished IGF-I feedback, as recognized in fasting and after pegvisomant injection [31].
Additional in vitro and animal studies are required to localize this hypothesized effect, that is,
the somatotroph and/or GHRH and ghrelin or somatostatin neurons. Thus, toremifene does
not change spontaneous and dual peptidyl-stimulated GH secretion in either sex, but pre-
vents GH amplification under putatively diminished IGF-I feedback restraint.
Depending on the route of administration, estrogens affect the synthesis of various proteins
in the liver, including GH-dependent IGF-I, two of its binding proteins, IGFBP1 and IGFBP3,
and SHBG. Other routes of administration of estrogens, that is, transdermal or intravaginal,
avoid first-pass liver effects, and they generally have less or no effect on these measures,
unless the dose is increased. In our study, toremifene resulted in a 20% decrease in serum
IGF-I concentrations in men and women with only a weak negative effect of visceral fat. An
IGF-I–lowering effect has been noted in a few other SERM studies. Tamoxifen in a 20-mg dose
lowers serum IGF-I in men and women, but raloxifene seems to have a lesser action (14% vs
20% to 25% in tamoxifen reports) and only at a high dose in women, but not in men [28, 32]. A
drawback of these studies is that they are rather small (about 10 subjects), and hence negative
results might be caused by lack of statistical power.
In regression analyses, separately done for the placebo and toremifene treatments, IGF-I
levels related positively to visceral fat and mean 10-hour GH concentrations and negatively to
age, as predicted from other studies on estrogen on IGF-I [1]. IGFBP3 is the major IGF-I–
binding protein that associates together with acid labile subunit to form a ternary complex,
regulated by GH. Most studies indicate that estrogens do not influence circulating IGFBP3
levels [33–35],with one exception [36]. Studies reporting effects of SERMson IGFBP3 levels are
rare. One study mentions that raloxifene increased IGFBP3 levels in postmenopausal women,
whereas estradiol diminished IGFBP3 [32]. Our findings of unchanged IGFBP3 levels during
toremifene administration are thus in line with reported absent effects of 17b-estradiol on the
concentration of this binding protein. The other important IGF-binding protein is IGFBP1,
which is regulated reciprocally by insulin, thereby raising levels of free IGF-I postprandially.
Higher free IGF-I confers anabolic effects.Estrogens increase serum IGFBP1concentration [34,
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37, 38]. However, no data on the effect of SERMs on this binding protein have been reported
previously. In this study, toremifene increased IGFBP1 levels by 1.4- and 1.5-fold in men and
women, respectively, during treatmentwith toremifene. A strong negative predictor of IGFBP1
levels during placebo and toremifene treatment was the fasting insulin concentration, in
agreement with literature data [39]. There were no evident factors thatmodulated the increase
of IGFBP1 by toremifene. Whether diminished bioavailable IGF-I, as inferred from this study,
is clinically relevant is not known. However, diminished free IGF-I during toremifene treat-
ment might restrict tumor growth in breast and prostate cancer. Moreover, IGF-I might also
promote the emergence of the metabolic syndrome after hormone deprivation.
Estradiol and other estrogens, including tamoxifen, elevate SHBG. For unclear reasons
raloxifene appears to lack this stimulating effect [32], but no independent studies are
available. In our study, we found an estrogen-like effect of toremifene to raise SHBG in men
andwomen to a similar extent. In theGLMprocedure visceral fatwas a significant interaction
factor, corroborated by the finding that the increase in SHBGdepended negatively on visceral
fat, although its magnitude was rather restricted.
Caveats of this study are the relative short time of drug administration and the fixed 60-mg
dose. Thus, different effects are possible on a higher dose and/or during prolonged treatment.
Alternatively, GH secretion was accurately quantified by the intensive blood sampling
procedure, and maximal GH release was explored by the combined injection of GHRH and
ghrelin. Importantly, note that single GH measurements do not reflect daily GH secretion.
Moreover, at present there are no data on the relationship between stimulatedGH release (by
any test) and spontaneous daily GH secretion [40].
4. Summary and Conclusions
This study uncovers the central antiestrogenic effects of toremifene. The precise site of this
action, either the somatotropes and/or hypothalamic neurons, is not known. Conversely,
toremifene induced several well-known effects of estradiol and tamoxifen on liver proteins.
From the perspective of cancer treatment, the 20% IGF-I decrease could be a favorable effect,
while unchangedGHsecretionwillmost likely protect tissues such as brain, bone, andmuscle.
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